1. Strategies for the Management of EGFR TKI Resistance in Advanced NSCLC

3. Program Goals

4. EGFR TKI Resistance

5. ATP and Erlotinib Binding to EGFR

6. Resistance to TKIs in Other Systems

7. When is Progression Significant Enough to Change Therapy?

8. The Need to Rebiopsy

9. Radiation With Concurrent Gefitinib or Erlotinib

10. Systemic Therapy

11. Rapid Progression With Discontinuation of EGFR TKI in Acquired Resistance

12. Leptomeningeal Disease

13. Afatinib vs Placebo (LUX-Lung 1): Phase 2b/3 Study

14. Afatinib + Cetuximab: Responses at MTD

15. Clinical Trials in NSCLC With Acquired Resistance

16. Abbreviations

17. Abbreviations (cont)

18. Abbreviations (cont)

19. References

20. References (cont)

21. References (cont)

22. References (cont)

23. References (cont)

24. References (cont)

25. References (cont)